QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AMRX

QT71Amneal Pharmaceuticals, Inc.
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
16.21
-0.07-0.43%
OverviewShort InterestFilings
AMRXQT71Amneal Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
16.21-0.43%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86
Snapshot
Index-P/E43.76EPS (ttm)
0.38
Insider Own-
Shs Outstand319.02M
Perf Week-0.80%
Market Cap5.19BForward P/E14.39EPS next Y1.13Insider Trans2.61%Shs Float-Perf Month37.26%
Enterprise Value7.69BPEG0.01EPS next Q0.24Inst Own-Short Float-Perf Quarter31.36%
Income118.42MP/S1.71EPS this Y158.35%Inst Trans-Short Ratio-Perf Half Y33.20%
Sales3.05BP/B-EPS next Y14.71%ROA3.46%Short Interest-Perf YTD28.65%
Book/sh-0.14P/C17.62EPS next 5Y15.60%ROE-144.72%52W High16.61 -2.41%Perf Year105.19%
Cash/sh0.62P/FCF25.30EPS past 3/5Y-ROIC12.64%52W Low7.67 111.34%Perf 3Y-
Dividend Est.-EV/EBITDA12.29Sales past 3/5Y10.92% 8.66%Gross Margin38.66%Volatility2.51% 2.32%Perf 5Y-
Dividend TTM-EV/Sales2.53EPS Y/Y TTM336.84%Oper. Margin11.80%ATR (14)0.53Perf 10Y-
Dividend Ex-Date-Quick Ratio1.59Sales Y/Y TTM9.06%Profit Margin4.02%RSI (14)77.99Recom2.38
Dividend Gr. 3/5Y-Current Ratio2.47EPS Q/Q28.57%SMA2014.37%Beta0.85Target Price17.33
Payout0.00%Debt/Eq-59.38Sales Q/Q4.03%SMA5021.36%Rel Volume1.64Prev Close16.28
Employees8,300LT Debt/Eq452.50EarningsAug 04SMA20030.86%Avg Volume1.72MPrice16.21
IPO DateMay 07, 2018Option/ShortYes / YesEPS/Sales Surpr.58.82% 0.42%Net Debt/EBITDA3.99Volume2,823,532Change-0.43%
Analyst Ratings
DateActionAnalystRatingTarget
May-20-26ReiteratedBarclaysOverweight$15 → $16
Apr-17-26InitiatedUBSBuy$19
Mar-02-26ReiteratedTruist Financial$15 → $17
Jan-07-26ReiteratedTruist Financial$14 → $15
Dec-08-25InitiatedBarclaysOverweight$11 → $15
Mar-03-25ReiteratedBarclaysOverweight$11
Feb-24-25UpgradeJP MorganNeutral → Overweight
Nov-11-24ReiteratedPiper SandlerOverweight$8.00 → $11
Oct-02-24ReiteratedTruist Financial$10 → $12
Oct-01-24ReiteratedTruist Financial$9.00 → $10
Latest News
Jun-16-26
Jun-16-2608:50AM
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid OverdoseBenzinga
Jun-15-26
Jun-15-2608:51AM
Top 3 Health Care Stocks That May Collapse This QuarterBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,0473,0192,794
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1,8681,8831,774
Gross Profit1,1771,1361,020
Selling, General and Administrative Excl. Other595527476
Research and Development186186191
Other Operating Expense380104
Operating Income360423249
Interest Expense237241259
Unusual Expense
———
Non-Operating Income (Expense)-604346
Net Income Before Taxes182139-55
Income Taxes11119
Consolidated Net Income12172-117
Net Income From Continuing Operations182128-74
Net Income12172-117
EPS (Recurring)0.380.23-0.38
EPS (Basic, Before Extraordinaries)0.380.23-0.38
EPS (Diluted)0.380.22-0.38
EBITDA627604440
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio42.6657.27—
Price To Sales Ratio1.751.31—
Gross Margin38.6337.6336.51
Operating Margin11.8114.018.91
Net Margin3.972.38-4.19
Shares Outstanding329313309
Market Capitalization5,3333,944—
Operating Lease Expense
———
Insider Trading Volume
$17.79$16.73$15.68$14.63$13.57● Close Price0.00M2.59M5.18M7.77M10.36MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Autor Deborah M.DirectorMay 11 '26Sale12.9434,819450,55893,660May 12 12:00 AM
BUCHI J KEVINDirectorMay 07 '26Option Exercise0.0069,638075,077May 08 12:00 AM
Autor Deborah M.DirectorMay 07 '26Option Exercise0.0069,6380128,479May 08 12:00 AM
Kiely JohnDirectorMay 07 '26Option Exercise0.0069,6380260,252May 08 12:00 AM
George Jeffrey P.DirectorMay 07 '26Option Exercise0.0069,6380344,614May 08 12:00 AM
Patel GautamDirectorMay 07 '26Option Exercise0.0069,63801,643,963May 08 12:00 AM
Nark Ted CDirectorMay 07 '26Option Exercise0.0069,6380325,848May 08 12:00 AM
MEISTER PAUL MDirectorMay 07 '26Option Exercise0.0097,4940832,800May 08 12:00 AM
Yanai ShlomoDirectorMay 07 '26Option Exercise0.0069,6380320,804May 08 12:00 AM
BOYER ANDREW SExecutive Vice PresidentMar 04 '26Option Exercise0.0076,3900445,208Mar 05 12:00 AM
Patel ChintuCo-CEOMar 04 '26Option Exercise0.00185,18601,417,504Mar 05 12:00 AM
Patel Chirag K.President & Co-CEOMar 04 '26Option Exercise0.00185,18601,431,295Mar 05 12:00 AM
Daly Jason B.EVP, Chief Legal OfficerMar 04 '26Option Exercise0.0071,7600267,364Mar 05 12:00 AM
Konidaris TasosExecutive Vice President & CFOMar 04 '26Option Exercise0.0093,9640471,469Mar 05 12:00 AM
Shah NikitaExecutive Vice PresidentMar 04 '26Option Exercise0.0071,7600417,769Mar 05 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR